Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 18;12:3742. doi: 10.1038/s41467-021-23957-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Graphic illustration of the changes in mRNA expression of genes defining mammary epithelial cell lineages after the suppression of oncogenic KRAS in claudin-low mammary tumor cells. b Immunoblot analysis to validate the upregulation of the luminal epithelial lineage and progenitor markers CD61 and GATA3 following Dox-mediated suppression of oncogenic KRAS for 72 h in three independent cell lines (N = 3 biological replicates). GAPDH was used as a loading control. c Flow cytometric analysis of CD24, CD49f, and CD61 in claudin-low mammary tumor cells before and after Dox-mediated suppression of oncogenic KRAS for 72 h. d Immunoblot analysis of E-cadherin and N-cadherin, SLUG, and SNAIL (N = 3 biological replicates for each treatment group). e Immunoblot analysis to assess changes in E-cadherin expression following shRNA-mediated knockdown of SLUG and Dox-mediated suppression of oncogenic KRAS (N = 3 biological replicates).